Madopar

Levodopa/benserazide, the active ingredient in Madopar, is a Levodopa/dopa decarboxylase inhibitor combination presented as a tablet for oral use. It treats Parkinson's disease and Parkinsonian syndrome in adults.

GNH USA supplies Madopar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our network includes major healthcare institutions across Europe, Asia, Africa and the Americas, providing consistent access to essential antiparkinson therapy.

Madopar, a Levodopa/dopa decarboxylase inhibitor combination, is used in the management of Parkinsonian movement disorders. - Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor. - Parkinsonian syndrome: alleviates motor dysfunction in secondary or drug‑induced Parkinsonism. - Levodopa‑responsive Parkinsonism: provides symptomatic relief in patients who respond to dopaminergic therapy.

Madopar may cause a range of adverse reactions, varying from mild to potentially serious.

Common Side Effects: - Nausea - Vomiting - Orthostatic hypotension - Dizziness - Headache - Insomnia

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Severe hypertension - Cardiac arrhythmias - Psychosis or hallucinations - Severe depression - Allergic reactions such as skin rash or angioedema

When prescribing Madopar, clinicians should consider several precautionary measures to ensure patient safety. - Assess cardiovascular status: monitor for orthostatic hypotension and arrhythmias. - Review psychiatric history: levodopa may exacerbate psychosis or mood disorders. - Evaluate renal and hepatic function: dose adjustments may be needed in impairment. - Avoid abrupt discontinuation: risk of withdrawal and worsening symptoms. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at room temperature below 25°C: keep in original container, protect from moisture and light.

Madopar can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis; avoid concurrent use. - Selective MAO‑B inhibitors (e.g., selegiline) at high doses: may cause severe hypertension. - Antipsychotics (especially dopamine antagonists): may diminish therapeutic effect. - Anticholinergic agents: may mask levodopa side effects, complicating management. - High‑dose pyridoxine (vitamin B6): accelerates peripheral levodopa metabolism, reducing efficacy.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive blood pressure lowering; monitor orthostatic changes. - Diuretics: may increase risk of hypotension. - SSRIs/SNRIs: monitor for serotonin syndrome when combined with MAO inhibitors. - Iron supplements: may reduce levodopa absorption; separate dosing times. - Protein‑rich meals: can compete with levodopa absorption; advise timing of medication.